---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-064829"
form_type: "8-K"
ticker: "CYTK"
cik: "0001061983"
company_name: "CYTOKINETICS INC"
filed_at: "2023-11-17T23:59:59+00:00"
generated_at: "2026-06-07T23:49:08.607036+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Cytokinetics amends bylaws to strengthen stockholder meeting and proxy procedures

## Summary
- Requires director nominees under universal proxy rules to comply with SEC rules and provide evidence.
- Enhances advance notice disclosures: stockholders must provide background info on nominees and interested persons.
- Mandates that soliciting stockholders use a proxy color other than white.
- Clarifies Board's ability to adjourn or postpone stockholder meetings.
- Conforms provisions to Delaware General Corporation Law; includes administrative updates.

## SEC filing metadata
- accession: 0000950170-23-064829
- form_type: 8-K
- ticker: CYTK
- cik: 0001061983
- company_name: CYTOKINETICS INC
- filed_at: 2023-11-17T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 3.03, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1061983/000095017023064829/0000950170-23-064829-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1061983/000095017023064829/cytk-20231116.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-064829
- JSON: https://secwatch.observer/filing/0000950170-23-064829.json
- Plain text: https://secwatch.observer/filing/0000950170-23-064829.txt

## Key facts
- Governance Changes
  CYTOKINETICS INC: Amended and restated bylaws to update advance notice provisions, universal proxy rule compliance, proxy color requirement, stockholder meeting conduct, and conform to Delaware law (effective 2023-11-16).
  - Change: bylaw amendment
  - Effective: 2023-11-16
  source text: On and effective as of November 16, 2023, the Board of Directors (the “Board”) of Cytokinetics, Incorporated (the “Company”) approved and adopted an amendment and restatement of the Amended and Restated Bylaws of the Company (as so amended and restated, the “Revised Bylaws”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1061983/000095017023064829/0000950170-23-064829-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.